Dapagliflozin for the treatment of type 1 diabetes mellitus

ABSTRACT

Introduction: In 2017, the management of type 1 diabetes mellitus (T1DM) remains intriguing for the clinician, who has to balance between adequate glycemic control and untoward events related to insulin up-titration. Thus, agents that will complement insulin actions and reduce adverse effects are highly welcome.

Areas covered: In this review, the authors summarize results from studies on the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin in T1DM.

Expert opinion: In T1DM, dapagliflozin is associated with significant antihyperglycemic and metabolic properties, which are achieved with reduction or stabilization of insulin dose and with a very low trend for hypoglycemia. However, there is a lot to learn with respect to diabetic ketoacidosis (DKA), bone fractures and lower limb ischemia.

KEYWORDS:

• Dapagliflozin
• SGLT2 inhibitors
• treatment
• type 1 diabetes mellitus
• untoward effects

Declaration of interest

N. Papanas has been an advisory board member of TrigoCare International, Astra-Zeneca, Boehringer Ingelheim, MSD, Novo Nordisk and Pfizer; has participated in sponsored studies by Astra-Zeneca, GSK, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for Astra-Zeneca, Boehringer Ingelheim, Eli-Lilly, ELPEN, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and received travel grants from TrigoCare International, Eli-Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis. E. Maltezos has participated in sponsored studies by Astra-Zeneca, GSK, Novo Nordisk, Novartis and Sanofi-Aventis; and received travel grants from Wyeth, Pfizer, and Bayer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.